Evofem Biosciences, Inc.
SEC Document
SEC Filing

Evofem Biosciences, Inc. (the “Company”) held its Annual Meeting of Stockholders on September 14, 2023 (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders approved a resolution to amend the Company’s existing Amended and Restated Certificate of Incorporation (“Certificate”). The Company’s stockholders approved: (i) an amendment to the Certificate to increase the total number of common shares authorized for issuance by the Company to 3,000,000.000. Detailed descriptions of the amendments to the Certificate are contained in the definitive proxy statement for the Annual Meeting, filed with the Securities and Exchange Commission on August 29, 2023.


The Board previously approved the amendment to the Certificate, subject to and conditioned upon stockholder approval at the Annual Meeting. Following stockholder approval of the amendment to the Certificate at the Annual Meeting, the Company prepared an Amended and Restated Certificate of Incorporation to reflect the amendment. The Amended and Restated Certificate of Incorporation is effective as of September 15, 2023.